Search research articles
Contact Us
Filters
Showing results (211-220 of 226) with videos related to
Page
of 23
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
July 29, 2024
SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression
Xiangyuan Luo, Wenjie Huang, Siwen Li, et al.
Gut
|
February 27, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
Zerui Zhang, Wenjie Huang, Dian Hu, et al.
Science China. Life Sciences
|
February 9, 2018
42,573 cases of hepatectomy in China: a multicenter retrospective investigation
Binhao Zhang, Bixiang Zhang, Zhiwei Zhang, et al.
International Journal of Surgery (London, England)
|
November 25, 2025
Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study
Feng Xia, Xulin Liu, Jing Yan, et al.
BJS Open
|
November 5, 2025
Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study
Feng Xia, Yiyang Liu, Hongwei Huang, et al.
Science China. Life Sciences
|
September 14, 2025
A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study
Feng Xia, Jing Yan, Xulin Liu, et al.
Journal of Hepatology
|
December 21, 2020
Association of liver abnormalities with in-hospital mortality in patients with COVID-19
Ze-Yang Ding, Gan-Xun Li, Lin Chen, et al.
Hepatology International
|
July 9, 2020
Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases
Chihua Fang, Jihyun An, Antonio Bruno, et al.
The Lancet. Oncology
|
June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren, Jianming Xu, Yuxian Bai, et al.
The Lancet. Gastroenterology & Hepatology
|
May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Yinghong Shi, Guohong Han, Jian Zhou, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 226) with videos related to
Sort By:
Page
of 23
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
July 29, 2024
SOX12 Facilitates Hepatocellular Carcinoma Progression and Metastasis through Promoting Regulatory T-Cells Infiltration and Immunosuppression
Xiangyuan Luo, Wenjie Huang, Siwen Li, et al.
Gut
|
February 27, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
Zerui Zhang, Wenjie Huang, Dian Hu, et al.
Science China. Life Sciences
|
February 9, 2018
42,573 cases of hepatectomy in China: a multicenter retrospective investigation
Binhao Zhang, Bixiang Zhang, Zhiwei Zhang, et al.
International Journal of Surgery (London, England)
|
November 25, 2025
Clinical and economic outcomes of robotic-assisted, laparoscopic, and open liver resection in BCLC 0/A hepatocellular carcinoma: a nationwide cohort study
Feng Xia, Xulin Liu, Jing Yan, et al.
BJS Open
|
November 5, 2025
Risk factors for hepatocellular carcinoma rupture: multicentre retrospective study
Feng Xia, Yiyang Liu, Hongwei Huang, et al.
Science China. Life Sciences
|
September 14, 2025
A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study
Feng Xia, Jing Yan, Xulin Liu, et al.
Journal of Hepatology
|
December 21, 2020
Association of liver abnormalities with in-hospital mortality in patients with COVID-19
Ze-Yang Ding, Gan-Xun Li, Lin Chen, et al.
Hepatology International
|
July 9, 2020
Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases
Chihua Fang, Jihyun An, Antonio Bruno, et al.
The Lancet. Oncology
|
June 18, 2021
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study
Zhenggang Ren, Jianming Xu, Yuxian Bai, et al.
The Lancet. Gastroenterology & Hepatology
|
May 23, 2025
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Yinghong Shi, Guohong Han, Jian Zhou, et al.
Page
of 23